Category: Orphan Drug Designation

CAMP4 Therapeutics has received the FDA Orphan Drug Designation (ODD) for its clinical-stage therapeutic, CMP-CPS-001, which treats urea cycle disorders (UCDs). The therapy, which employs regulatory RNA-targeting technology,...